A Phase 2 Study of the Safety and Efficacy of INCB050465, a Selective PI3Kδ Inhibitor, in Combination with Ruxolitinib in Patients with Myelofibrosis

被引：4
|
作者：
Daver, Naval G. [1 ]
Kremyanskaya, Marina [2 ]
O'Connell, Casey [3 ]
Dao, Kim-Hien [4 ]
Oh, Stephen T. [5 ]
Gerds, Aaron T. [6 ]
Verstovsek, Srdan [1 ]
Erickson-Viitanen, Sue [7 ]
Zhou, Feng [7 ]
Assad, Albert [7 ]
Yacoub, Abdulraheem [8 ]
机构：
[1] Univ Texas MD Anderson Canc Ctr, Houston, TX 77030 USA
[2] Mt Sinai Hlth Syst, New York, NY USA
[3] Univ Southern Calif, Los Angeles, CA USA
[4] Oregon Hlth & Sci Univ, Portland, OR 97201 USA
[5] Washington Univ, Sch Med, St Louis, MO USA
[6] Cleveland Clin, Taussig Canc Inst, Cleveland, OH 44106 USA
[7] Incyte Corp, Wilmington, DE USA
[8] Univ Kansas, Med Ctr, Kansas City, KS 66103 USA
来源：
BLOOD | 2018年 / 132卷
关键词：
D O I：
10.1182/blood-2018-99-111338
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
353
引用
收藏
页数：3
相关论文
共 50 条
  • [21] A Phase 1/2 Study of INCB000928 as Monotherapy or in Combination with Ruxolitinib in Patients with Anemia Due to Myelofibrosis (INCB 00928-104).
    Oh, Stephen T.
    Kiladjian, Jean-Jacques
    Palandri, Francesca
    Gotlib, Jason R.
    Mohan, Sanjay
    Ali, Haris
    Asatiani, Ekatherine
    Seguy, Francis
    Zhou, Feng
    Verstovsek, Srdan
    CANCER RESEARCH, 2021, 81 (13)
  • [22] A Phase 1/2 Study of INCB000928 as Monotherapy or in Combination with Ruxolitinib in Patients with Anemia Due to Myelofibrosis (INCB 00928-104)
    Oh, Stephen
    Kiladjian, Jean-Jacques
    Palandri, Francesca
    Gotlib, Jason
    Mohan, Sanjay
    Ali, Haris
    Asatiani, Ekatherine
    Seguy, Francis
    Zhou, Feng
    Verstovsek, Srdan
    BRITISH JOURNAL OF HAEMATOLOGY, 2021, 193 : 111 - 112
  • [23] Safety and Efficacy of Pelabresib in Combination With Ruxolitinib for JAK Inhibitor-Naive Patients With Myelofibrosis: Latest Data From the Phase 3 MANIFEST-2 Study
    Mascarenhas, John
    Rampal, Raajit K.
    Grosicki, Sebastian
    Chraniuk, Dominik
    Abruzzese, Elisabetta
    Bose, Prithviraj
    Gerds, Aaron
    Vannucchi, Alessandro M.
    Palandri, Francesca
    Lee, Sung-Eun
    Gupta, Vikas
    Lucchesi, Alessandro
    Oh, Stephen T.
    Kuykendall, Andrew T.
    Patriarca, Andrea
    Alvarez-Larran, Alberto
    Mesa, Ruben
    Kiladjian, Jean-Jacques
    Talpaz, Moshe
    Lavie, David
    Harris, Morgan
    Kays, Sarah-Katharina
    Jegg, Anna Maria
    Wu, Manlei
    Brown, Barbara
    Harrison, Claire
    CLINICAL LYMPHOMA MYELOMA & LEUKEMIA, 2024, 24 : S416 - S417
  • [24] Phase 2 study of the safety and efficacy of umbralisib in patients with CLL who are intolerant to BTK or PI3Kδ inhibitor therapy
    Mato, Anthony R.
    Ghosh, Nilanjan
    Schuster, Stephen J.
    Lamanna, Nicole
    Pagel, John M.
    Flinn, Ian W.
    Barrientos, Jacqueline C.
    Rai, Kanti R.
    Reeves, James A.
    Cheson, Bruce D.
    Barr, Paul M.
    Kambhampati, Suman
    Lansigan, Frederick
    Pu, Jeffrey J.
    Skarbnik, Alan P.
    Roeker, Lindsey
    Fonseca, Gustavo A.
    Sitlinger, Andrea
    Hamadeh, Issam S.
    Dorsey, Colleen
    LaRatta, Nicole
    Weissbrot, Hanna
    Prak, Eline T. Luning
    Tsao, Patricia
    Paskalis, Dana
    Sportelli, Peter
    Miskin, Hari P.
    Weiss, Michael S.
    Svoboda, Jakub
    Brander, Danielle M.
    BLOOD, 2021, 137 (20) : 2817 - 2826
  • [25] A PHASE 1 STUDY OF PATIENTS WITH RELAPSED OR REFRACTORY CLASSICAL HODGKIN LYMPHOMA TREATED WITH A PI3K DELTA INHIBITOR (INCB040093) ALONE OR IN COMBINATION WITH A SELECTIVE JAK1 INHIBITOR (INCB039110)
    Forero-Torres, A.
    Barr, P.
    Diefenbach, C.
    Sher, T.
    Schaub, R.
    Zhou, L.
    Pulini, J.
    Leopold, L.
    Spear, M.
    Talpaz, M.
    Phillips, T.
    HAEMATOLOGICA, 2015, 100 : 112 - 112
  • [26] A phase 2 study of ruxolitinib in combination with azacitidine in patients with myelofibrosis
    Masarova, Lucia
    Verstovsek, Srdan
    Hidalgo-Lopez, Juliana E.
    Pemmaraju, Naveen
    Bose, Prithviraj
    Estrov, Zeev
    Jabbour, Elias J.
    Ravandi-Kashani, Farhad
    Takahashi, Koichi
    Cortes, Jorge E.
    Ning, Jing
    Ohanian, Maro
    Alvarado, Yesid
    Zhou, Lingsha
    Pierce, Sherry
    Gergis, Romany
    Patel, Keyur P.
    Luthra, Rajyalakshmi
    Kadia, Tapan M.
    DiNardo, Courtney D.
    Borthakur, Gautam
    Bhalla, Kapil
    Garcia-Manero, Guillermo
    Bueso-Ramos, Carlos E.
    Kantarjian, Hagop M.
    Daver, Naval
    BLOOD, 2018, 132 (16) : 1664 - 1674
  • [27] A PHASE 1 STUDY OF PATIENTS WITH RELAPSED OR REFRACTORY B-CELL MALIGNANCIES TREATED WITH A PI3K DELTA INHIBITOR (INCB040093) ALONE OR IN COMBINATION WITH A SELECTIVE JAK1 INHIBITOR (INCB039110)
    Phillips, T.
    Forero-Torres, A.
    Sher, T.
    Diefenbach, C.
    Talpaz, M.
    Scherle, P.
    Schaub, R.
    Zhou, L.
    Pulini, J.
    Leopold, L.
    Spear, M.
    Barr, P.
    HAEMATOLOGICA, 2015, 100 : 110 - 110
  • [28] Safety and Efficacy of Combined Ruxolitinib and Thalidomide in Patients with Myelofibrosis: A Phase II Study
    Rampal, Raajit K.
    Verstovsek, Srdan
    Devlin, Sean M.
    King, Amber C.
    Stein, Eytan M.
    Pemmaraju, Naveen
    Mauro, Michael J.
    Kadia, Tapan M.
    Montalban-Bravo, Guillermo
    Alvarez, Kelsey
    Ard, Nicole
    Goodman, Tawni
    Taylor, Bria
    Bose, Prithviraj
    BLOOD, 2019, 134
  • [29] Phase 1 study of the safety and efficacy of INCB050465 combined with obinutuzumab and bendamustine for relapsed or refractory (R/R) follicular lymphoma (FL) (CITADEL-102).
    Coleman, Morton
    Salar, Antonio
    Munoz, Javier
    Galanina, Natalie
    Faivre, Thea
    Zinzani, Pier Luigi
    JOURNAL OF CLINICAL ONCOLOGY, 2017, 35
  • [30] Preliminary Results from a Phase I Dose Escalation Trial of Ruxolitinib and the PI3Kδ Inhibitor TGR-1202 in Myelofibrosis
    Moyo, Tamara K.
    Sochacki, Andrew
    Ayers, Gregory D.
    Byrne, Michael T.
    Strickland, Stephen A.
    Mohan, Sanjay R.
    Harrison, Jill
    Berry, Lynne D.
    Dudley, Channing V.
    Severs, Rachel
    Dugger, Laura
    Miskin, Hari P.
    Cavers, Amy
    Sportelli, Peter
    Michaelis, Laura C.
    Mesa, Ruben A.
    Savona, Michael R.
    BLOOD, 2016, 128 (22)
12345